Korean biotechnology companies are successfully completing initial public offerings at the top of their indicative price ranges, securing smooth fundraising. An Korean biotechnology companies are successfully completing initial public offerings at the top of their indicative price ranges, securing smooth fundraising. Analysts attribute this trend to biotech firms with solid revenue track records or licensing deal achievements entering the market. According to the Korea Exchange and other sources on the 11th, all biotech companies that conducted book-building this year have priced their IPOs at the upper end of their indicative ranges.

Original title: “Korean Biotech IPOs Surge as All 2024 Listings Price at Top Range - Seoul Economic Daily”

Backpack Exchange is working with Superstate to bring IPOs on-chain, moving beyond tokenized stocks toward blockchain infrastructure for capital markets. Backpack’s role in this model is likely to act as the distribution layer. Through the exchange, users could sign up for potential allocations in upcoming IPOs. If selected, their ownership would be reflected through on-chain records tied to the newly issued shares. That distinction matters. Global equity markets are worth roughly $150 trillion. However, the annual IPO market or the segment Backpack is targeting with on-chain offerings typically ranges between $50 billion and $150 billion a year. Now, some companies are trying to push the idea further and move the entire process onchain by making IPOs native or on-chain first. Backpack Exchange, founded by Armani Ferrante, is beginning to explore whether the IPO process itself can move onto blockchain rails. The exchange is expanding its U.S.

Original title: “How an Exchange Led by Former CFTC Chairman Is Making On-Chain IPOs a Reality”

Whether happening in public or private, biopharma M&A is fiercer than ever. Experts point to patent pressures, herd mentality and a declining stock of available biotechs with mature assets.

Original title: “Pharma Is Ravenous for M&A Action but Late-Stage Supply Dwindles”

The Kanakee project builds on the company’s efforts to increase its U.S. footprint, where it has already spent more than $3 billion, and will focus on producing plasma-derived therapies.

Original title: “CSL breaks ground on $1.5B Illinois immunoglobulin plant expansion”

Ugur Sahin and Özlem Türeci, who directed the COVID vaccine maker’s rise to prominence, will helm an as-yet-unnamed company dedicated to mRNA discovery work.

Original title: “BioNTech founders to step down and helm new mRNA startup”

The move comes as BioNTech shifts to being a multiproduct commercial biotech, allowing Ugur Sahin and Özlem Türeci to transition back into research on next-generation mRNA therapeutics.

Original title: “BioNTech Founders To Leave Famed mRNA Biotech for New Venture”

Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production.

Original title: “Cell and Gene Therapy Manufacturing Market To Skyrocket to $146B by 2032”

Breakout Ventures’ focus on early-stage companies stands out as more and more investors elect to save their dollars for derisked assets.

Original title: “AI-Focused Fund Breakout Raises $114M To Support Early-Stage Biotechs”

Stylus Medicine, a member of BioSpace’s NextGen Class of 2026, launched in May 2025 to develop new, less complex genetic medicines. The company’s in vivo approach has attracted “intense” interest from Big Pharma.

Original title: “Rising Amid Flurry of CAR T Deals, Stylus Proves Cell Therapy Is Not Dead”

Pharmaceutical and biotechnology ... research organizations (CROs) that provide essential trial management services. The Global Rare Disease Clinical Trials Market is projected to reach USD 30.13 billion by 2033. The market is expected to grow at a compound annual growth rate (CAGR) of 9.39% from 2026 to 2033. A global pharmaceutical company that develops and markets innovative therapies, including treatments for rare ... Pharmaceutical and biotechnology firms lead the market as they drive most clinical trial initiatives, supported by contract research organizations (CROs) that provide essential trial management services. The Global Rare Disease Clinical Trials Market is projected to reach USD 30.13 billion by 2033. The market is expected to grow at a compound annual growth rate (CAGR) of 9.39% from 2026 to 2033. A global pharmaceutical company that develops and markets innovative therapies, including treatments for rare diseases. A British-Swedish multinational pharmaceutical and biotechnology company that is actively involved in rare disease clinical trials. A Swiss multinational pharmaceutical company that has a diverse portfolio of rare disease treatments and a robust pipeline of investigational therapies. The growth of the Rare Disease Clinical Trials Market is crucial for developing orphan drugs and ensuring regulatory compliance, as well as accelerating market approvals in key regions. Increasing government support for orphan drug development, rising awareness about rare diseases, and advances in gene therapies and molecular diagnostics are the primary growth drivers for the market. Rare diseases, which often affect a small fraction of the population, pose unique challenges in diagnosis, treatment, and drug development, leading pharmaceutical companies and research organizations to invest heavily in clinical trials targeting these niche patient populations.

Original title: “Rare Disease Clinical Trials Market to Reach $30.13B by 2033 - Austin Today”

Single-trial approvals are raising the bar on trial design and execution. The new paradigm is pushing sponsors to plan earlier, step up their data and risk‑based quality management and use modeling and AI to generate one compelling, regulator‑ready evidence package.

Original title: “Single Pivotal Trials Demand Stronger Data and Risk Strategies”

Industry groups have identified upfront costs as a barrier to streamlining U.S. drugmaking. The nonprofit API Innovation Center has a proposed answer for how to tilt finances in favor of investments in continuous manufacturing.

Original title: “Nonprofit Aims to Modernize Manufacturing by Clearing Capital Hurdle”

A handful of the worst performing companies in the IPO class of 2025 are staring down the risk of a “negative feedback loop” as selling restrictions for long-term investors and management teams are lifted after earnings, according to the head of PricewaterhouseCoopers’ US listing practice. This month, ticket seller Stubhub Holdings Inc. and cybersecurity company Netskope Inc. are facing a combination of earnings and the expiration of restrictions on insiders selling shares following their respective IPOs. StubHub signage during the company's IPO at the New York Stock Exchange on Sept.

Original title: “Beaten Down IPOs Face ‘Negative Feedback Loop’ After Lock-Ups - Bloomberg”

Prasad contributed to an uncertain regulatory climate for gene therapy makers focused on rare conditions. Shares of many developers rose on the chance of a more industry-friendly successor.

Original title: “UniQure leads genetic medicine biotech rally after news of Prasad’s exit”

Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme and that it has struggled to sell.

Original title: “Ipsen to withdraw cancer drug acquired in buyout due to safety concerns”

The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that could increase access to Novo’s obesity medicines.

Original title: “Novo Nordisk Agrees To Sell GLP-1 Drugs Via Hims & Hers, Ending Dispute”

The agreement ends a messy dispute that began when the telehealth firm attempted to sell a compounded form of Novo’s Wegovy pill at a cheaper price.

Original title: “Novo, Hims reach deal to sell GLP-1 drugs together”

Some biotechs that had seen regulatory setbacks under Center for Biologics Evaluation and Research director Vinay Prasad experienced stock bumps Monday morning. Under Prasad’s leadership, the rare disease space has suffered a series of controversial rejections.

Original title: “Prasad’s Departure Could Be ‘Big Win’ for Biotech—Especially Rare Disease Space: Analysts”

The M&A momentum continued in February with several large strategic deals across energy, telecom, finance, infrastructure, biotech, and technology — signaling continued consolidation and large-scale capital deployment. Large deals announced during the month demonstrate how companies and investors ... The M&A momentum continued in February with several large strategic deals across energy, telecom, finance, infrastructure, biotech, and technology — signaling continued consolidation and large-scale capital deployment. Large deals announced during the month demonstrate how companies and investors are investing to strengthen market position, scale operations, and expand into new areas such as AI, digital The Intellizence dataset highlights key M&A deals for February 2026, including multi-billion-dollar acquisitions across energy, telecom, finance, infrastructure, biotech, and technology. Biopharmaceutical company Gilead Sciences plans to acquire Arcellx, a developer of advanced cancer therapies, in a deal valued at up to $7.8 billion. Arcellx specializes in cell therapies for hematologic cancers, particularly CAR-T treatments. The transaction reflects continued biotech consolidation as pharmaceutical companies acquire innovative drug developers. Deals can be funded through cash, stock, debt financing, or a combination.

Original title: “Top 10 Largest Global Merger & Acquisition Deals – February 2026 | Intellizence Top 10 Largest M&A Deals - February 2026”

Spend enough time inside a healthcare distribution center and you start to notice something.

Original title: “Rethinking the box: Why circular cold chain packaging is becoming a cost strategy in healthcare”